Thus far, down-regulation of CDK12-dependent HR genes is being explored as an approach to eliminate cancer cells, most notably in combination with PARP1 inhibitors or DNA-damaging chemotherapeutics (28,29). This evidence concerns the gene PARP1 and cancer.